Humacyte (HUMA) Prices $50 Million Public Stock Offering

Humacyte, Inc. (NASDAQ: HUMA) announced Wednesday that it has priced an underwritten public offering expected to raise approximately $50 million in gross proceeds to support commercialization efforts and advance its product pipeline.

The offering consists of 47.6 million shares of common stock priced at $1.05 per share. The transaction is expected to close on or around June 12, 2026, subject to customary closing conditions.

In addition, Humacyte granted underwriters a 30-day option to purchase up to an additional 7.1 million shares of common stock at the public offering price, less underwriting discounts and commissions.

The company said all shares in the offering are being sold directly by Humacyte.

Humacyte plans to use the net proceeds from the offering to support the commercialization of Symvess®, fund activities related to a planned Biologics License Application (BLA) supplement filing for a hemodialysis indication, advance development programs across its product pipeline, and provide additional working capital for general corporate purposes.

The financing comes as Humacyte continues developing bioengineered human tissues designed for implantation across multiple medical applications. The company focuses on creating universally implantable tissue products intended to address unmet needs in vascular repair and regenerative medicine.

Barclays, BTIG, and Titan Partners, a division of American Capital Partners, are serving as joint book-running managers for the offering.

Biotechnology companies commonly use public stock offerings to raise capital for clinical development, regulatory activities, product commercialization, and ongoing research initiatives. The proceeds from the transaction are expected to strengthen Humacyte’s financial position as it pursues growth opportunities and expands its commercial operations.